Dr. Samantha South discusses Patrys' repurposing of quetiapine for delirium treatment and regulatory strategy.
Summary
Dr. Samantha South, CEO of Patrys (ASX: PAB), explains the company's strategy to repurpose AstraZeneca's quetiapine as an intravenous formulation (RLS-2202) for treating delirium. She defines delirium as an acute brain dysfunction triggered by factors like surgery or infection, estimating 8-20 million episodes annually. The company is leveraging the FDA 505(b)(2) pathway to utilize existing safety data, avoiding redundant toxicology studies. Phase One trials are underway, with Cohort One complete and Cohort Two recruiting healthy volunteers to confirm IV safety. South notes that while AstraZeneca focuses on chronic care, Patrys targets the acute care market, aiming for a Phase Three data readout before seeking licensing partners.
Episode sections
- 0:03 – 1:42
Introduction and Company Overview
Henry Jennings introduces Dr. Samantha South, CEO of Patrys (ASX: PAB), highlighting her background in CNS drug development.
- 1:42 – 4:21
Delirium Pathology and Market Opportunity
Dr. South defines delirium as an acute brain dysfunction and estimates the addressable market at 8-20 million episodes annually.
- 4:21 – 7:09
Drug Repurposing: RLS-2202 and Quetiapine
Discussion on repurposing AstraZeneca's quetiapine as an IV formulation (RLS-2202) for acute care, leveraging existing safety data.
- 7:09 – 9:42
Phase One Trial Progress and Recruitment
Update on Phase One trials: Cohort One complete, Cohort Two recruiting 12 healthy volunteers in Adelaide to confirm IV safety.
- 9:42 – 14:52
Regulatory Pathway and IP Strategy
Explanation of the FDA 505(b)(2) pathway and patent strategy based on the 'inventive step' of solubilizing quetiapine for IV use.
- 14:52 – 29:15
Commercialization and Funding Strategy
Plans to license RLS-2202 after Phase Three, seeking capital efficiency through non-dilutive incentives and strategic partnerships.
Claims worth verifying
Delirium is an acute brain dysfunction triggered by vulnerability and an event like infection or surgery, causing confusion, agitation, and hallucinations.
Unidentified speaker (speaker_1) ·1:42
How to verify: Medical literature on delirium pathophysiology; clinical guidelines from health organizations (e.g., NICE, APA). For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
There are up to 8-20 million episodes of delirium annually across ICU, post-operative, aged care, and palliative settings.
Unidentified speaker (speaker_1) ·3:01
How to verify: Epidemiological studies on delirium incidence; hospital admission statistics from health departments in the US and Australia. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceDelirium episodes increase the risk of long-term cognitive decline and dementia.
Unidentified speaker (speaker_1) ·3:39
How to verify: Longitudinal medical studies linking delirium to dementia outcomes; neurology journals. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Quetiapine (Cerequel) has been used for schizophrenia and bipolar disorder for about four decades.
Unidentified speaker (UNKNOWN) ·4:36
How to verify: FDA approval history for quetiapine; AstraZeneca product lifecycle documents. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Patrys is using the FDA 505(b)(2) pathway to leverage AstraZeneca's safety data for quetiapine.
Unidentified speaker (speaker_1) ·9:42
How to verify: FDA guidance on 505(b)(2) applications; Patrys investor presentations or regulatory filings referencing this pathway. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceDelirium costs the US hospital system $164 billion and the Australian system $9 billion.
Unidentified speaker (UNKNOWN) ·23:39
How to verify: Health economics studies; reports from US Centers for Medicare & Medicaid Services (CMS) or Australian Department of Health. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Phase One Cohort One is complete, and Cohort Two recruitment has started in Adelaide for 12 healthy volunteers.
Unidentified speaker (UNKNOWN) ·7:09
How to verify: Patrys clinical trial updates; ClinicalTrials.gov registration for RLS-2202; CMAX trial announcements. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Phase Two trials for RLS-2202 will be conducted in Australia only.
Unidentified speaker (UNKNOWN) ·21:37
How to verify: Patrys trial design documents; regulatory correspondence with TGA (Therapeutic Goods Administration). For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Patrys expects to complete last dosing in December and finalize Phase One in Q1 of the following year.
Unidentified speaker (speaker_1) ·20:15
How to verify: Patrys corporate calendar; investor updates for the relevant year (2026/2026). For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the specific excipients and formulation differences between RLS-2202 and oral quetiapine by reviewing Patrys' patent filings.
- Check the FDA 505(b)(2) regulatory requirements for repurposed drugs to assess the validity of the claim that toxicology studies are unnecessary.
- Review AstraZeneca's public disclosures regarding their intellectual property assignments and strategic focus on chronic vs. acute care.
- Monitor the recruitment status and results of Patrys' Phase One Cohort Two trial for safety signals in healthy volunteers.
- Assess the competitive landscape for delirium treatments, including any competing IV formulations or novel therapeutics in development.
- Confirm the timeline for the pre-IND meeting with the FDA planned for Q1 next year as stated by Dr. South.
- Evaluate the patent application's strength regarding the 'inventive step' claim by analyzing prior art on quetiapine solubility.
- Review Patrys' financial filings for details on current funding, capital efficiency strategies, and potential dilution risks.
Full transcriptexpand
0:03Unidentified speaker (UNKNOWN): Well,
0:04Henry Jennings: welcome to another episode of On the Couch with myself Henry Jennings from Marcus Today, and today I am delighted to be joined by Dr. Samantha South from Patries. The stop code there is PAB. I met Samantha down in Melbourne at the MicroCap conference, and I've
0:21Unidentified speaker (UNKNOWN): been
0:21Henry Jennings: trying to get her on the show for some time, and it's only just happened. So I'm really delighted to get Samantha. on the show. It's um it's going to be really interesting, I think, today. Now it is a micro cap stock, so uh bear that in mind. But uh, you know, from small things, big things grow. So that is the that is the principle behind this to some extent. So so welcome, Samantha, and thanks very much for coming on.
0:45Unidentified speaker (speaker_1): Thank you, thank you so much for having us. me.
0:47Henry Jennings: Now, Dr. Samantha, I'll just give her a brief intro, is an experienced biotech. executive with deep expertise in CNS drug development. And she spent a career cultivating expertise in drug development, management of non-clinical studies, project management, contracts, IP manufacturing, and clinical operations. So very well qualified Uh, to be uh the CEO of uh Patries Patrice and very well qualified to talk to us today. So and as usual, with all the information contained in this podcast, it is general advice only. So, please do your own research. Contact your own financial advisor regarding any of the thoughts, ideas, or insights in this podcast. Samantha, thank you again for coming on. Tell us about delirium and and the problem that you are trying Are to solve with your um well, I was gonna say new drug, but it's it's an old drug but that you're you're really repurposing it in a new way. I think that's fair to
1:41Unidentified speaker (UNKNOWN): say.
1:42Unidentified speaker (speaker_1): Yeah, um that's the best way to say it actually. Um delirium is uh a condition, um it's a an acute brain dysfunction that can occur
1:54Unidentified speaker (UNKNOWN): uh
1:55Unidentified speaker (speaker_1): usually when you have um there's some sort of vulnerability that you have, so some sort of um
2:01Unidentified speaker (UNKNOWN): uh
2:02Unidentified speaker (speaker_1): vulnerable brain condition, and then it's triggered by something. So it could be triggered by infection, it could be triggered by um uh surgical procedure, dehydration. There's lots of reasons that that can trigger it. So this is why you know everyone who has an operation doesn't always end up with delirium. So there has to be both of those factors there. It's um causes confusion, it causes agitation and it causes um sometimes hallucinations and agitation. So it covers a little bit of ground uh as far as symptoms, but it is actually all because of a a a chemical storm that happens inside your brain where a lot of neurotransmitters are affected and so therefore um sometimes non non-pharmacological pharmacological treatments just cannot work. to help um alleviate the delirium.
2:53Henry Jennings: And how big
2:55Unidentified speaker (UNKNOWN): uh
2:55Henry Jennings: how big is the opportunity I guess with um with treating this delirium?
3:01Unidentified speaker (speaker_1): Yeah, so uh if you there's a couple of uh acute we use it for acute care settings, so things like ICU, uh post-operative post operative care, aged care facilities where people have had as as I said, say an infection and they've had a delirium event,
3:19Unidentified speaker (UNKNOWN): or
3:19Unidentified speaker (speaker_1): in palliative care settings. And so if you include all of those different settings, then the the there's up to eight to twenty million possibilities for episodes. Each patient can have more than one episode. The whole point is that we want to make sure that they have fewer episodes and that the episodes of delirium are not as long because if they if they have more episodes and if they have long episodes of delirium, then you're more likely to to stay in that cognitive decline place. And so there is actually more more of a risk that you'll end up with dementia.
3:57Unidentified speaker (UNKNOWN): I
3:57Henry Jennings: was gonna say, does th delirium lead to dementia or is it kind of all wrapped up in in in part of the same story to some extent?
4:05Unidentified speaker (speaker_1): Yeah, so um people with dementia and Parkinson's and uh those kind of conditions have that vulnerable g brain condition that I was sort of mentoring. They already have a vulnerable brain.
4:15Unidentified speaker (UNKNOWN): And
4:16Unidentified speaker (speaker_1): so they are more likely to end up with delirium based on a trigger such as surgery or infection.
4:21Henry Jennings: Fair enough. Now um the drug you're um using is is an old drug, isn't it? It's an AstraZeneca blockbuster, uh Cerequel, is that right? Um and and you're repurposing it uh to some extent. Tell us about that.
4:36Unidentified speaker (UNKNOWN): Yeah,
4:36Unidentified speaker (speaker_1): so Cerequel's been around for about four decades. It's been used for schizophrenia and bipolar disorder, but it's always been used chronically. So the idea from AstraZeneca's point of view was to try and extend the dose. So for them the focus has always been about extended release, you know, once daily dosing, chronic dosing of this drug. So they, but as a part of that process, they've done a lot of work on the safety. So where we've repurposed this into an you know an IV formulation that's more for the acute care setting. But we can leverage all of that research and all of that. data that AstraZeneca has already developed for the chronic care indications.
5:20Henry Jennings: And this is quiterapine, is that
5:23Unidentified speaker (UNKNOWN): how you
5:23Henry Jennings: I
5:23Unidentified speaker (speaker_1): call it quitiapine?
5:25Unidentified speaker (UNKNOWN): Quitiopene.
5:26Henry Jennings: Quitiopene, I I think you are saying it right. RLS twenty two quitiapine. And Uh what's the difference between this and uh Cerequel? Is it just the IV solution?
5:41Unidentified speaker (speaker_1): So it's the full formulation. So uh we're not taking the oral formulation as a whole and putting it into an IV solution. We've actually had to r reformulate it. So it's got entirely different excipients to what would go into the oral formulation. So um the the only thing that's the same is the the drug substance, the API, the active pharmaceutical ingredient, which is the quatiapine. Everything else is different. And because of that, we had to prove that there's no new uh issues with our IV formulation that the oral formulation doesn't already have. So a lot of the phase one data that we're doing at the moment is about proving that our product is just as safe as. is just as good, and has just as much and and to determine those dosing that's the similar to what the oral product delivers.
6:35Henry Jennings: Right. And who's who's making the solution at the moment for you? Is that something you're doing in house or is that an outhouse set solution?
6:43Unidentified speaker (speaker_1): So everything that we do is outsourced,
6:45Unidentified speaker (UNKNOWN): I So
6:45Unidentified speaker (speaker_1): guess. yes. Uh it's an outsourced model.
6:47Henry Jennings: Yeah.
6:47Unidentified speaker (speaker_1): Biosena is the company out that's based out of Western Australia. that uh that are producing our drug product for us at the moment.
6:55Henry Jennings: Right, Biosena. Excellent. So so where are you in terms of this pathway? You're talking about the phase one uh trial to prove that it um is is is safe or is as safe as the uh the old AstraZeneca drug. Uh how's that going?
7:09Unidentified speaker (UNKNOWN): Yeah,
7:09Unidentified speaker (speaker_1): no, it's really good. So we've completed our exploratory part of the uh phase one, which was cohort one.
7:15Unidentified speaker (UNKNOWN): And
7:15Unidentified speaker (speaker_1): that was designed to demonstrate how much of the oral formulation actually reaches the bloodstream in comparison to what the IV and comparison to what our IV dose
7:24Henry Jennings: does.
7:25Unidentified speaker (speaker_1): The assumption is that 100% of what you deliver IV will reach the bloodstream. So cohort one gives us a measure of the estimate of the oral bivavailability, bioilability, and then we can use that to calculate the IV dose. for the next part of the study. Cohort two, which is we're kicking off, we're already kicked off for recruitment. By the way, if you are in Adelaide, please go see CMAX. We need as many healthy volunteers as we can find. In fact, cohort two is designed to confirm that the injectable formulation raises no additional safety concerns. And because we can get that dose right early with the with the data that we'll get out of the cohort too, we can keep on track with our with our development work and make sure that it's efficient for all those next trials that we're doing.
8:16Henry Jennings: And how long does it normally take to recruit patients to these trials? That you're you're after 12 healthy volunteers, is that right?
8:23Unidentified speaker (speaker_1): Yeah, so we started we we've started with a month, that's usually enough time to find twelve volunteers. I guess it
8:30Unidentified speaker (UNKNOWN): you
8:30Unidentified speaker (speaker_1): know it depends on the type of study. Every study's a little bit different. Um and there's a level of confinement where you're you're not allowed to leave uh the the study site. So um
8:43Unidentified speaker (UNKNOWN): you
8:43Unidentified speaker (speaker_1): know there's always depends on the length of the study, depends on the the timing and things like that.
8:49Henry Jennings: Right.
8:49Unidentified speaker (UNKNOWN): So
8:49Henry Jennings: how long you're are you locked up?
8:53Unidentified speaker (speaker_1): It's about five days.
8:54Henry Jennings: Oh wow.
8:58Unidentified speaker (speaker_1): Yeah, but you basically get to just watch TV and eat as much as you want.
9:02Henry Jennings: Sounds like
9:02Unidentified speaker (UNKNOWN): COVID.
9:03Henry Jennings: Sounds sounds like one of those lockdown things when you came back from COVID and and you were locked in a hotel for two weeks.
9:09Unidentified speaker (speaker_1): No, I think it would be like the perfect thing for a student that's just finished all their exams and they just get to relax.
9:16Henry Jennings: Yeah. And binge on Netflix, all those series they've missed while they've been studying.
9:21Unidentified speaker (speaker_1): Exactly.
9:21Henry Jennings: Well, there you go. There's your market right there. You've identified it very well. Now, um, you you talk about um the FDA five oh five B two pathway in some of your uh announcements. Maybe you could just elaborate a little bit on on that regulatory shortcut and what it means for you a small company like you with the with this new drug.
9:42Unidentified speaker (speaker_1): Yeah so the 505v2 is a an FDA pathway for regulatory approval that allows us to leverage all of that data that AstraZeneca has um provided for cotiopine and what basically it says you don't need to redo everything. You don't need to reinvent the wheel we already know that this drug this this API is safe. And so therefore, as long as you're not doing anything to change what how that API behaves, you can then leverage all of the data that that they've already shown. So we don't need to redo any of the reproductive studies. We don't need to redo any of the talk studies. But what we will need to show is as I said that ours is just as safe and then we can um leverage all of that data and we do need to show that our product will be efficacious in um d patients with delirium as well.
10:34Henry Jennings: Right. So why don't I mean I I this is probably an obvious question or an obvious answer. Why why don't companies like AstraZeneca um take this this it's their drug, it's obviously come off patent. Uh Why why doesn't a company like AstraZeneca take it this step further uh and get involved in these sorts of uh these sorts of trials?
10:53Unidentified speaker (speaker_1): Um there's a couple of reasons. Re uh one yes, I did go and talk to AstraZeneca as soon as I uh started on this project. Um they're no longer um they've actually assigned all of the IP to a distribution company for this, so they're actually not interested in this. Um from an acute um care care setting, um there's there's a specialty sort of drug uh company that does those sort of things. So AstraZeneca being a large farmer is a little
11:22Unidentified speaker (UNKNOWN): bit
11:22Unidentified speaker (speaker_1): less that kind of hospital related um farm um
11:26Unidentified speaker (UNKNOWN): uh
11:27Unidentified speaker (speaker_1): program I guess or or um
11:30Henry Jennings: yeah
11:31Unidentified speaker (speaker_1): uh yeah uh anyway and um the other thing was that the the solubility of quotiapine quatiopine is like actually really low. And uh it was really hard to to come up with a formulation that would actually work intravenously that didn't cause like pain when you delivered it. Because while there's been a quite a few patent applications about trying to solubise quatiopine, most of them have to go into a p a low pH before you can actually solubilize
12:00Unidentified speaker (UNKNOWN): it.
12:01Unidentified speaker (speaker_1): So there was a lot of it was a lot of work and um
12:05Unidentified speaker (UNKNOWN): you know
12:05Unidentified speaker (speaker_1): the acute care setting is is probably less of an interest for a company like AstraZeneca than schizophrenia or bipolar or any of those long-term chronic diseases.
12:16Henry Jennings: So um you've obviously got the IP for um RLS 2202. Are there any other companies um out there nipping at your heels and have got similar things happening in the space and you are maybe using even the same uh formulation from AstraZeneca?
12:33Unidentified speaker (UNKNOWN): I
12:34Unidentified speaker (speaker_1): know, so
12:35Unidentified speaker (UNKNOWN): the
12:35Unidentified speaker (speaker_1): AstraZeneca formulations were all oral, so they're very different.
12:39Henry Jennings: Right.
12:39Unidentified speaker (speaker_1): Um, very different formulations. And that while there are pattern applications regarding intravenous formulations, most of them, as I said, weren't from a practical point of view. able to be delivered. So while you can, you know, find a formulation that will make it soluble, you couldn't, they couldn't quite find a formulation that was soluble and could be delivered with the with the right pH and the right osmolity into your vein. So
13:07Unidentified speaker (UNKNOWN): that
13:07Unidentified speaker (speaker_1): was really hard and it took a lot of effort. It took RELIS the company that Patris acquired several years to sort of work through. And because of that, because it took you know a lot of research and a lot of trial and error to find
13:23Unidentified speaker (UNKNOWN): that,
13:23Unidentified speaker (speaker_1): that's going to show to the patent examiners that it wasn't easy, it wasn't obvious, and it wasn't there was an inventive step that was required. And so those are the that's how you actually get a patent application is because you have to show that it's inventive and non-obvious.
13:39Henry Jennings: So
13:39Unidentified speaker (speaker_1): we think that that means that um
13:41Unidentified speaker (UNKNOWN): the
13:41Unidentified speaker (speaker_1): chances of getting our patent application are
13:44Unidentified speaker (UNKNOWN): I
13:44Unidentified speaker (speaker_1): mean you never know
13:45Unidentified speaker (UNKNOWN): but
13:46Unidentified speaker (speaker_1): the chances are higher because of those those steps, those clear steps. But it also means that we've come up with our own workarounds. So we've tried all of the excipients to to find what works. So if somebody else comes up with something chances are it's probably still in our patent application because we we've tried most of those. So we've kind of put the the flag in the sand for all of those um potential opportunities. So yes, somebody there might be a new recipient that might come up in several years, but then that then they'd have have to be fighting for us for market share.
14:19Unidentified speaker (UNKNOWN): I
14:19Henry Jennings: think I've learned a new word today. Osmo Osmolality.
14:23Unidentified speaker (speaker_1): Osmolality,
14:24Unidentified speaker (UNKNOWN): yeah.
14:25Unidentified speaker (speaker_1): sorry.
14:25Henry Jennings: That That's that's that's a great new word. I've I've learned. I'm gonna have to
14:28Unidentified speaker (speaker_1): if you have the wrong one, it causes you to hurt.
14:33Henry Jennings: I'm sure it's very painful. Now now in terms of the uh the business model and uh how you're gonna commercialise this, clearly, you know, you you've got a little way to go yet, uh phase one uh underway. But um what's the ultimate kind of prize here? Is it to be taken out by a a bigger farmer or is this gonna be a kind of royalty model or how how are you going to commercialise this?
14:58Unidentified speaker (speaker_1): Um yeah, so the idea is for this not to be our only asset.
15:03Henry Jennings: Right.
15:04Unidentified speaker (speaker_1): So uh you know, rolling forward for the future, the the hope is that we can either um have a co-development agreement or
15:13Unidentified speaker (UNKNOWN): uh
15:14Unidentified speaker (speaker_1): ultimate ultimately a license for a company that is highly specialized in distributing to the hospital system in the way that this is you know will be required. And so that they will actually license the CIP and then Patras itself will continue on the next asset. So the idea isn't that we we
15:33Unidentified speaker (UNKNOWN): have
15:34Unidentified speaker (speaker_1): one hit, I shall we say, um, but that we then um use the funding. from that license to keep other assets going. So the plan is definitely uh co-development or licensing in the future. Um you know how far you have to go usually you have to go to at least phase three because that's um at this point in time that's what all pharmaceutical companies are unless you have a really, really really highly novel um asset. um then which a reformulation play is is not those hundredx highly novel assets so um but most companies are actually wanting you especially in highly competitive um
16:20Unidentified speaker (UNKNOWN): uh
16:20Unidentified speaker (speaker_1): indications are are wanting to you to to be at least phase three you you have to show that there's some efficacy you have to show that there's there's some chance that we'll it will be successful.
16:30Henry Jennings: I I guess being uh a reformulation of a of a already successful drug that's been around for four decades, that kind of endpoint is is somewhat easier to get to is it than than if you're doing something from scratch?
16:44Unidentified speaker (speaker_1): Yeah in general if you have a reformulation or a repurposing play you're about two to three times more likely to be successful just simply because you're not uh a lot of the risk is on that safety aspect and we don't have any risk around safety at the moment. So
17:00Henry Jennings: Right.
17:01Unidentified speaker (UNKNOWN): Now
17:01Henry Jennings: now you've got another asset you talked about um other assets. Uh deoxymab is is that um the other asset that you're you're alluding
17:09Unidentified speaker (UNKNOWN): to?
17:10Unidentified speaker (speaker_1): Um so that's that was the historical asset. for Patrice.
17:13Henry Jennings: Right.
17:14Unidentified speaker (speaker_1): Um we've we've uh negotiated with Yale to to make sure that we're no longer paying for the patent costs and sort
17:22Unidentified speaker (UNKNOWN): of
17:22Unidentified speaker (speaker_1): the upfront costs. Um but that we'll make sure that we keep the upside to any commercialization endeavours that happens with that asset. So we're continuing to fund um some research in vasculitis through Monash University.
17:39Unidentified speaker (UNKNOWN): And
17:39Unidentified speaker (speaker_1): so we're continuing to play a part in its development, but um a very modest part.
17:44Henry Jennings: Fair enough. Now I guess the uh the question with all small biotech companies is how much money you've
17:51Unidentified speaker (UNKNOWN): got,
17:51Henry Jennings: um how much money you're burning, and uh how you plan to to fund uh phase 1b, one B, 2a, two A, etc. Uh what other funding options are being considered. apart, I guess, from uh from equity capital raises?
18:07Unidentified speaker (speaker_1): Yeah, so like all small cap companies, we recognise that the balance sheet is a real constraint. And but our programs are very much planned to be focused on being capital efficient and to make sure that we uh can make the most out of every dollar spent. We have a budget that we're developing for the phase two A study, but the final cost for that will actually depend on the trial design, the number uh and the the feedback that we'll receive from the FDA for our pre-IND meeting that's uh earmarked for Q1 of next year. So we'll definitely re
18:43Unidentified speaker (UNKNOWN): you
18:43Unidentified speaker (speaker_1): know provide more detail on the cost of timing and the timing of that study, but we need to make sure that the design is fine finalized with regulatory alignment. So we're waiting for
18:54Unidentified speaker (UNKNOWN): that.
18:55Unidentified speaker (speaker_1): We're always considering options. Um, we have, you know, we know what cash we currently hold. We've got access to non-dilutive sources such as the RD incentives, um, and we're always looking for strategic partnering. Where appropriate, we'll we'll obviously have to um aim for more equity funding. But the aim is for us to pursue the best combination that supports the program while limiting dilution and
19:27Unidentified speaker (UNKNOWN): de
19:27Unidentified speaker (speaker_1): best definitely considering the interests of our existing shareholders.
19:31Henry Jennings: It's always a tricky one, isn't it? Because um you know th there is a tendency, I guess, for um for shareholders to wait till you get to further down the track, as you say, phase three, uh, before they get really excited, and that does take a little while to get to. What does do shareholders have to look forward to? You know, we're coming up to Christmas. I can't believe this year has gone quite as fast as it has, but we are coming up to Christmas. What would shareholders be expecting, or what would you like shareholders to be clapping you for? uh and uh you know standing on their chairs and going,
20:05Unidentified speaker (UNKNOWN): Yeah,
20:05Henry Jennings: this is happening. Uh what would what would you expect twenty twenty seven to look like in terms of announcements, in terms of trial results, etc.? How does that look for you?
20:15Unidentified speaker (speaker_1): Yeah, so we'll we'll complete last dosing in December. Um but then obviously you've So it takes a while for all the results to come through. So the anticipation is that um we'll find finalize the phase one in
20:29Unidentified speaker (UNKNOWN): in
20:29Unidentified speaker (speaker_1): gen in um Q one.
20:32Henry Jennings: Yeah.
20:33Unidentified speaker (speaker_1): Uh while it's um information about proving whether or not our drug is actually just as safe as the oral dose in in healthy volunteers, it's kind of really important. So it's both um,
20:47Unidentified speaker (UNKNOWN): you
20:48Unidentified speaker (speaker_1): know, something that's not highly risky. but really important because if we don't have that information we can't put everything in front of the FDA, we can't get alignment for the for the next two studies. So I think that you know from my perspective, it'd be it'd be really nice if shareholders understood that yes, uh completing your phase one and moving through that those processes of getting FDA alignment are actually really really important to to move. moving forward.
21:16Unidentified speaker (UNKNOWN): And
21:16Unidentified speaker (speaker_1): then starting our phase two, that's going to be very exciting. So because that'll be testing our drug in the actual patient population that we'll be wanting this to um
21:26Unidentified speaker (UNKNOWN): you
21:26Unidentified speaker (speaker_1): know be be a product for.
21:28Henry Jennings: And and is that phase two uh a a local phase two or is that international or is that just US? Um where are you going to be recruiting your patients from?
21:37Unidentified speaker (UNKNOWN): Yeah
21:37Unidentified speaker (speaker_1): no the phase two will definitely be Australia only. And this means that we won't have to open uh a full investigational new drug program with that with the FDA until we go into the phase three trials. Usually makes things a little bit easier and a little bit uh um less expensive to stay in Australia for your phase two.
21:56Unidentified speaker (UNKNOWN): It
21:57Unidentified speaker (speaker_1): also because it's once again a bit of a bridging study as opposed to a a a full uh safety study for a phase two, because most phase twos are more safety and a little bit of efficacy, because we don't have to have that large safety aspect to it um in in our patient population still, um, it's going to be a much smaller trial than the majority of other phase twos would be if it was in a different indication or or with an absolutely new uh chemical entity.
22:25Henry Jennings: Right. Fair enough. Now um I I I I'm loath to say this, but you you are a a a nano cap company, I think a market cap around six
22:36Unidentified speaker (UNKNOWN): six
22:39Henry Jennings: six okay you're a l you're a you're a large cap compared to uh to many. Uh you're you're capped capped at around sixteen million dollars. How hard is it to uh you know to um to jump up and down, I guess, and and say, Come on, look at me guys, look at me, we're we're exciting and all it's a happening thing. Is that is that a hard thing to attract investor interest?
23:02Unidentified speaker (UNKNOWN): Yeah,
23:02Unidentified speaker (speaker_1): there's I guess there's a general view that until you reach about a hundred million market cap, um it's very hard. So but
23:12Unidentified speaker (UNKNOWN): I
23:12Unidentified speaker (speaker_1): don't know. It's about I guess resonating with the shareholders and seeing them, you know, having them understand that delirium is an absolute underserved, unmet need. There's very little competition. You know, we've got
23:28Unidentified speaker (UNKNOWN): uh
23:28Unidentified speaker (speaker_1): the ability to to have traction because, you know, peop the clinicians are crying out for something. Hospitals can see the value that this can add because
23:39Unidentified speaker (UNKNOWN): you
23:39Unidentified speaker (speaker_1): know, delirium costs these um hospital system a hundred and sixty four billion in America and nine billion in Australia. So,
23:50Unidentified speaker (UNKNOWN): you
23:50Unidentified speaker (speaker_1): know, there's absolutely it ticks every single box that makes success likely. And I just have to make sure
23:58Unidentified speaker (UNKNOWN): that,
23:58Unidentified speaker (speaker_1): you know, people understand that I guess. It's all on
24:01Unidentified speaker (UNKNOWN): me.
24:03Henry Jennings: Well it's not not all on you. I I guess one of the problems is that it's you know delirium itself is is one of those conditions that I guess gets a little bit overlooked and and possibly easy to get confused with um you know dementia and Alzheimer's etc. Is that fair to say?
24:20Unidentified speaker (speaker_1): Oh yeah absolutely and in the past it it has been sort of considered more of a a symptom rather than the a acute brain condition that it actually is. So it is important to to to to sort
24:33Unidentified speaker (UNKNOWN): of
24:34Unidentified speaker (speaker_1): have people understand that you know there is a a mechanism that happens with delirium and it there is actually something that you can target.
24:42Unidentified speaker (UNKNOWN): And
24:42Unidentified speaker (speaker_1): cry typing definitely targets all the things that go wrong in delirium. So from a mechanistic point of view, it's it's you
24:50Unidentified speaker (UNKNOWN): know
24:50Unidentified speaker (speaker_1): it's a really good drug to say that all the targets that are affected in delirium, cortiopine can actually help with. Um it's also I mean, there's um three different versions of delirium. So there's the hypoactive, which is really where you're really quite calm.
25:11Unidentified speaker (UNKNOWN): And
25:12Unidentified speaker (speaker_1): the hyperactive, which means you're agitated. and then a mixed version because you can fluctuate between the two.
25:18Unidentified speaker (UNKNOWN): And
25:18Unidentified speaker (speaker_1): so agitated patients are really easy to notice, right?
25:21Unidentified speaker (UNKNOWN): You can sort
25:22Unidentified speaker (speaker_1): of see if they're hallucinating and things like that. It's a little bit harder when when patients have that calm. Usually it's only the family members who who really know. Well, hang on, that's not the person I know. That's not the person I love. So
25:37Unidentified speaker (UNKNOWN): I
25:37Unidentified speaker (speaker_1): think also a little bit. of it is about um
25:41Unidentified speaker (UNKNOWN): um
25:41Unidentified speaker (speaker_1): educating the clinicians. So it it wasn't really looked at in the past, so and coding was very different, but now it's actually it's in the guidelines that at the same time as checking pain, you now have to check delirium. So that's becoming easier to diagnose and that's helping with with the condition moving forward and with our treatment moving forward. Um so the clinical guidelines are becoming um easier to use a more routine um assessment and then now we just need to come up with a a therapy that works because you know a little bit like Alzheimer's who cares if you can diagnose it if there's no drugs for it, right? So
26:22Henry Jennings: but
26:22Unidentified speaker (speaker_1): now if we can show that there is a drug for it, then people will screen for it and then we can actually help people.
26:29Henry Jennings: It's it's a very worthy cause having uh been down the the dementia Alzheimer's route myself um with uh with my with my mother it's um it's it's a horrible thing and anything you can do
26:39Unidentified speaker (UNKNOWN): uh
26:40Henry Jennings: not just with Alzheimer's obviously in dementia but uh with delirium i is it's massively worthwhile. So Doctor Dr. Samantha thank you very much for uh appearing
26:49Unidentified speaker (UNKNOWN): on
26:49Henry Jennings: the show today. Thoroughly enjoyed it. Great chat. And uh if if there's one kind of elevator pitch that you could leave uh some of our listeners with in terms of uh Patris, what would that be?
27:05Unidentified speaker (UNKNOWN): Well
27:05Henry Jennings: I put you on the spot, haven't
27:07Unidentified speaker (UNKNOWN): I?
27:08Unidentified speaker (speaker_1): I mean, you know, the pat the focus for Patrice Patras is definitely helping patients.
27:14Henry Jennings: Yeah.
27:15Unidentified speaker (speaker_1): And delirium patients are not getting the help they need. And so um for us it you know, we want to be as capital efficient, we wanna make sure that the shareholders have a win, but we also want to shake make sure that the patients have a win. Um I don't know if that's
27:32Henry Jennings: that's good enough for me. I I
27:34Unidentified speaker (UNKNOWN): I
27:34Henry Jennings: wish you all the luck. We we will um touch base hopefully uh in in twelve months' time. and see how you're progressing but in the meantime Dr. Samantha South thanks very much for uh your time today really do appreciate it and uh good luck with 2027
27:48Unidentified speaker (speaker_1): thank you thank you for your time